Business
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations businessNow exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with VandaAnnounced appointment of Chris Murphy as CFOAnnounced appointments of Susannah Gray, former CFO of Royalty Pharma, and Owen Hughes, current CEO of XOMA Royalty, to its Board of Directors SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the fin
About this update from Anaptysbio, Inc.
[{"type":"image","alt":"AnaptysBio, Inc.","displaySize":"","headline":null,"caption":"AnaptysBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/5dd7f30a0ad6f5e52c819b2cf00b5a83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.iih9fgXNbOAwMH5sv5aNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/5dd7f30a0ad6f5e52c819b2cf00b5a83","width":300,"height":85},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.iih9fgXNbOAwMH5sv5aNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/5dd7f30a0ad6f5e52c819b2cf00b5a83","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced appointment of Chris Murphy as CFO","length":44,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced appointments of Susannah Gray, former CFO of Royalty Pharma, and Owen Hughes, current CEO of XOMA Royalty, to its Board of Directors","length":142,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":385,"olType":false},{"type":"text","content":"SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.","length":304,"tagName":"p"},{"type":"text","content":"“Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and delivering an EBIT margin greater than 95%,” said Daniel Faga, president and chief executive officer. “With Chris Murphy joining as CFO, who brings deep business development and investment banking experience, our priority continues to be to protect our two royalty streams and return t...